Sight Sciences Inc.

2.88
-0.01 (-0.35%)
Jan 22, 2025, 3:49 PM - Market open
-0.35%
Bid 2.88
Market Cap 146.43M
Revenue (ttm) 80.20M
Net Income (ttm) -50.77M
EPS (ttm) -1.01
PE Ratio (ttm) -2.86
Forward PE -5.22
Analyst Hold
Ask 2.89
Volume 294,842
Avg. Volume (20D) 247,091
Open 2.86
Previous Close 2.89
Day's Range 2.81 - 2.98
52-Week Range 2.67 - 8.45
Beta 2.73

About SGHT

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthal...

Sector Healthcare
IPO Date Jul 15, 2021
Employees 214
Stock Exchange NASDAQ
Ticker Symbol SGHT

Analyst Forecast

According to 7 analyst ratings, the average rating for SGHT stock is "Hold." The 12-month stock price forecast is $5.25, which is an increase of 81.98% from the latest price.

Buy 28.57%
Hold 71.43%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Sight Sciences Inc. is scheduled to release its earnings on Mar 6, 2025, during market hours.
Analysts project revenue of $20.29M, reflecting a 8.21% YoY growth and earnings per share of -0.19, making a -13.64% decrease YoY.
5 months ago
-14.96%
Sight Sciences shares are trading lower after the ... Unlock content with Pro Subscription
8 months ago
+10.23%
Sight Sciences shares are trading higher after the company announced a $34 million patent infringement verdict against Alcon and its Hydrus Microstent.